Article
Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
Clinical lung cancer - 1 Jan 2021
Zhu Yan-Juan, Qu Xin, Zhan Dan-Dan, Chen Hui-Hui, Li Hai-Peng, Liu Li-Rong, Chen Xian, Liu Yi-Hong, Li Yong, Bai Jian-Ping, Ye Sheng, Zhang Hai-Bo
Abstract excerpt
BACKGROUND: There occurs huge heterogeneity in clinical outcomes for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs). The purpose of this study was to indicate genetic biomarkers predicting primary resistance of EGFR-TKIs in these patients. PATIENTS AND METHODS: Using a next-generation sequencing panel with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
